Introduction
tumour
MALIGNANCIES, TUMOUR, PROSTATE CANCER
Immune checkpoint inhibition has poor efficacy in prostate cancer, in part due to an immunosuppressive microenvironment and low tumour mutational burden relative to other malignancies.Radiotherapy has the potential to enhance anti-tumour effects of immune checkpoint blockade via multiple mechanisms, including stimulating antigen presentation, releasing proinflammatory signals from dying tumour cells, and enhancing the diversity of the intratumoral T-cell receptor repertoire.Lutetium-177 [